<DOC>
	<DOCNO>NCT01601990</DOCNO>
	<brief_summary>Double-blind , randomize , multicenter , multinational ( South Korea India ) , parallel group study The study divide three part : part 1 start initial 2 week exercise/diet program follow another 2 week single-blind placebo run-in period ; part 2 double-blind treatment period eligible patient randomize LC15-0444 50mg placebo group receive assigned treatment 24 week ; part 3 patient complete part 1 &amp; 2 consented receive another 28 week treatment LC15-0444 50mg . Screening test perform patient give write informed consent . After 2-week exercise/diet program accord generally recognize guideline , patient take placebo another 2 week continue exercise/diet program . When 2-week placebo run-in period complete , eligible patient assign either placebo 50 mg LC15-0444 1:1 ratio . During total 24- week treatment period part 2 randomization , patient visit investigational site Week 6 , 12 , 18 , 24 . Completing treatment placebo LC15-0444 50mg 24 week randomization , patient ask provide consent participate part 3 study patient receive LC15-0444 50mg regardless treatment receive part 2 study . During 28-week treatment period part 3 , patient visit investigational site Week 30 , 38 , 46 , 52 . Total study period screen 56 week per patient .</brief_summary>
	<brief_title>Phase 3 Trial Evaluate Efficacy Safety LC15-0444 Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Patients Type 2 Diabetes Mellitus 2 . Adults 18 75 age 3 . Patients HbA1c 7 % 11 % 4 . Patient receive diabetic medication within 6 week screen 5 . Patients sign consent form inform object , method , risk clinical study 1 . Patients type 1 diabetes mellitus , gestational diabetes , secondary diabetes 2 . Patients take needed take drug may affect control blood glucose significantly ( ex . glucocorticoid ) 3 . Patients experience myocardial infarction , unstable angina prior history coronary artery bypass surgery within 6 month prior screen , patient arrhythmia require treatment 4 . Patients NYHA class IIIV congestive heart failure 5 . Patients history hepatic cirrhosis 6 . Patients renal failure whose creatinine clearance less 60mL/min 7 . Patients dysfunctional thyroid gland ( abnormal level TSH ) 8 . Patients ALT , AST CPK exceed 2.5 time upper limit normal range 9 . Patients BMI 20 kg/m2 exceed 40 kg/m2 10 . Patients history asthma major skin allergy 11 . Patients take thyroid hormone , warfarin , dicoumarin digoxin . 12 . Patients history hypersensitivity metformin biguanides . 13 . Patients take sodium channel blocker last 6 week prior Visit 1 . 14 . Patients treat insulin glucagonlike peptide1 ( GLP1 ) analogue take thiazolidinediones ( Glitazone ) last 6 month prior Visit 1 . 15 . Patients reason investigator decide eligible study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>